{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T18:38:58Z","timestamp":1785263938989,"version":"3.55.0"},"reference-count":26,"publisher":"Society of Nuclear Medicine","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2024,3,26]]},"published-print":{"date-parts":[[2024,7]]},"DOI":"10.2967\/jnumed.123.267271","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T14:50:20Z","timestamp":1716475820000},"page":"1080-1086","source":"Crossref","is-referenced-by-count":7,"title":["True-Positive<sup>18<\/sup>F-Flotufolastat Lesions in Patients with Prostate Cancer Recurrence with Baseline-Negative Conventional Imaging: Results from the Prospective, Phase 3, Multicenter SPOTLIGHT Study"],"prefix":"10.2967","volume":"65","author":[{"given":"Mark T.","family":"Fleming","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick","family":"Hermsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei S.","family":"Purysko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Chau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian F.","family":"Chapin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2024,5,23]]},"reference":[{"key":"2024070106251413000_65.7.1080.1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.euf.2016.06.018","article-title":"Rationale for modernising imaging in advanced prostate cancer","volume":"3","author":"Padhani","year":"2017","journal-title":"Eur Urol Focus."},{"key":"2024070106251413000_65.7.1080.2","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Canc Netw."},{"key":"2024070106251413000_65.7.1080.3","doi-asserted-by":"crossref","first-page":"JCO2302128","DOI":"10.1200\/JCO.23.02128","article-title":"Systemic therapy update on 177lutetium-PSMA-617 for metastatic castration-resistant prostate cancer: ASCO guideline rapid recommendation update","volume":"11","author":"Garje","year":"2023","journal-title":"J Clin Oncol."},{"key":"2024070106251413000_65.7.1080.4","unstructured":"Mottet N Cornford P van den Bergh RCN . EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. EAU website. https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2023_2023-06-13-141145_owmj.pdf. Updated 2023. Accessed April 19, 2024."},{"key":"2024070106251413000_65.7.1080.5","unstructured":"Highlights of prescribing information: POSLUMA (flotufolastat F 18) injection. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216023s000lbl.pdf. Revised May 2023. Accessed April 19, 2024."},{"key":"2024070106251413000_65.7.1080.6","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.234922"},{"key":"2024070106251413000_65.7.1080.7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13550-020-00740-z","article-title":"Preclinical comparison of four [18F,natGa]rhPSMA-7 isomers: influence of the stereoconfiguration on pharmacokinetics","volume":"10","author":"Wurzer","year":"2020","journal-title":"EJNMMI Res."},{"key":"2024070106251413000_65.7.1080.8","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.234914"},{"key":"2024070106251413000_65.7.1080.9","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.255661"},{"key":"2024070106251413000_65.7.1080.10","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.252114"},{"key":"2024070106251413000_65.7.1080.11","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1007\/s00259-021-05346-8","article-title":"Kinetic analysis and optimisation of 18F-rhPSMA-7.3 PET imaging of prostate cancer","volume":"48","author":"Malaspina","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024070106251413000_65.7.1080.12","first-page":"205","article-title":"Uptake of 18F-rhPSMA-7.3 in PET imaging of prostate cancer: a phase 1 proof-of-concept study","volume":"37","author":"Malaspina","year":"2022","journal-title":"Cancer Biother Radiopharm."},{"key":"2024070106251413000_65.7.1080.13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11307-023-01867-w","article-title":"Quantitative and qualitative assessment of urinary activity of 18F-flotufolastat-PET\/CT in patients with prostate cancer: a post hoc analysis of the LIGHTHOUSE and SPOTLIGHT studies","volume":"26","author":"Kuo","year":"2024","journal-title":"Mol Imaging Biol."},{"key":"2024070106251413000_65.7.1080.14","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1016\/j.ijrobp.2022.07.585","article-title":"Impact of clinical factors on 18F-rhPSMA-7.3 detection rates in men with recurrent prostate cancer: findings from the phase 3 SPOTLIGHT study [abstract]","volume":"114","author":"Lowentritt","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2024070106251413000_65.7.1080.15","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/JU.0000000000003493","article-title":"Diagnostic performance and safety of 18F-rhPSMA-7.3 PET in men with suspected prostate cancer recurrence: results from a phase 3, prospective, multicenter study (SPOTLIGHT)","volume":"210","author":"Jani","year":"2023","journal-title":"J Urol."},{"key":"2024070106251413000_65.7.1080.16","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.ijrobp.2023.06.302","article-title":"Detection rate of 18F-rhPSMA-7.3 PET in patients with suspected prostate cancer recurrence at PSA levels <1 ng\/mL: data from the phase 3 SPOTLIGHT study [abstract]","volume":"40","author":"Jani","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2024070106251413000_65.7.1080.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2009.10.015"},{"key":"2024070106251413000_65.7.1080.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)02411-1"},{"key":"2024070106251413000_65.7.1080.19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2004.04927.x"},{"key":"2024070106251413000_65.7.1080.20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4573"},{"key":"2024070106251413000_65.7.1080.21","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","article-title":"Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial","volume":"5","author":"Fendler","year":"2019","journal-title":"JAMA Oncol."},{"key":"2024070106251413000_65.7.1080.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2006.04.029"},{"key":"2024070106251413000_65.7.1080.23","first-page":"3065","article-title":"[68Ga]-PSMA-11 can clarify equivocal lesions on conventional imaging and change management decisions among men with previously treated prostate cancer [abstract]","volume":"63","author":"Gulhane","year":"2022","journal-title":"J Nucl Med."},{"key":"2024070106251413000_65.7.1080.24","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41391-022-00544-3","article-title":"The impact of PSMA PET on the treatment and outcomes of men with biochemical recurrence of prostate cancer: a systematic review and meta-analysis","volume":"26","author":"Pozdnyakov","year":"2023","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"2024070106251413000_65.7.1080.25","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.3390\/cancers15072027","article-title":"PSMA-PET guided treatment in prostate cancer patients with oligorecurrent progression after previous salvage treatment","volume":"15","author":"Bianchi","year":"2023","journal-title":"Cancers (Basel)."},{"key":"2024070106251413000_65.7.1080.26","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13014-023-02302-8","article-title":"Long-term outcomes of SBRT for PSMA PET detected oligometastatic prostate cancer","volume":"18","author":"Mohan","year":"2023","journal-title":"Radiat Oncol."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.123.267271","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T13:30:59Z","timestamp":1719840659000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.123.267271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":26,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,1]]},"published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.2967\/jnumed.123.267271"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.123.267271","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,23]]}}}